The market expects Invesco (IVZ) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 22, might help the stock move higher if these key numbers are better than exp ...

The market expects KeyCorp (KEY) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Jul ...

Capital One (COF) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 22. On t ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Lockheed Martin (LMT) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 22, might help the stock move higher if these key numbers are better than expectation ...

Core Viewpoint - Northrop Grumman (NOC) is expected to report a year-over-year increase in earnings despite lower revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate for Northrop Grumman's quarterly earnings is $6.70 per share, reflecting a year-over-year increase of +5.4% [3]. - Revenues are projected to be $10.11 billion, which is a decrease of 1.1% compared to the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 0.56%, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Northrop Grumman is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +3.10% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Northrop Grumman currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat despite the positive Earnings ESP [12]. Historical Performance - In the last reported quarter, Northrop Grumman was expected to post earnings of $6.21 per share but delivered $6.06, resulting in a surprise of -2.42% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Conclusion - While Northrop Grumman may not be a compelling earnings-beat candidate, investors should consider other factors when making investment decisions ahead of the earnings release [17].

Wall Street expects a year-over-year decline in earnings on lower revenues when NVR (NVR) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lowe ...

Core Viewpoint - GE Aerospace is expected to report strong second-quarter 2025 results, with earnings projected at $1.43 per share and revenues at $9.7 billion, reflecting year-over-year growth of 19.2% and 17.9% respectively [1][6]. Earnings Estimates - The earnings estimate for the current quarter has increased by $0.01 over the past week, indicating a positive trend [2]. - The consensus estimate for quarterly revenues is $9.7 billion, showing a year-over-year growth of 17.9% [1][6]. Earnings Surprise History - GE Aerospace has consistently outperformed earnings estimates, with an average surprise of 18% over the last four quarters [2]. Earnings Prediction - The company has a positive Earnings ESP of +4.94% and a Zacks Rank of 1 (Strong Buy), suggesting a high likelihood of an earnings beat [3]. Segment Performance - The Commercial Engines & Services segment is expected to generate revenues of $7.43 billion, reflecting a sequential growth of 6.5% due to strong demand for its engine platforms [4]. - The Defense & Propulsion Technologies segment is anticipated to achieve revenues of $2.57 billion, indicating a 10.5% sequential increase, driven by rising defense budgets and demand for commercial air travel [5]. Operational Investments - GE has been investing in expanding and upgrading manufacturing facilities in the U.S., which is expected to enhance operational capacity and meet increased demand [6][7]. Portfolio Restructuring - The completion of the Vernova spin-off has allowed GE to focus on its core aerospace business, improving operational focus and financial flexibility [8]. Cost Challenges - High costs and operating expenses from restructuring activities and supply chain challenges may impact performance [9]. Stock Performance - GE Aerospace's shares have increased by 43.8% over the past three months, outperforming the Zacks Aerospace-Defense industry and the S&P 500 [10]. Valuation Metrics - The company is trading at a forward P/E ratio of 43.47X, which is higher than the industry average of 27.51X, indicating potential vulnerability to market sentiment shifts [12]. Investment Outlook - The robust portfolio and strength in aerospace and defense markets are expected to drive performance, with organic revenue growth projected in the low-double-digit range for 2025 [15]. - The company's focus on reducing operational costs and improving margins is expected to enhance long-term cash flow [16]. - Given the positive analyst sentiment and growth prospects, the current market conditions may be favorable for potential investors [18].

Core Insights - Novartis AG is set to report its second-quarter 2025 results on July 17, with revenue expectations at $14.04 billion and earnings at $2.38 per share [1] - The company has a strong earnings surprise history, beating estimates in the last four quarters with an average surprise of 7.12% [1] Earnings Prediction - The Earnings ESP for Novartis is -0.28%, indicating a lower likelihood of an earnings beat this quarter [3] - The company currently holds a Zacks Rank of 2 (Buy) [3] Growth Drivers - Novartis operates in four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology following the spin-off of the Sandoz business [4] - Key products driving growth include Entresto, Kisqali, Kesimpta, Leqvio, and Scemblix, with strong sales expected in Q2 [4][8] Product Performance - Entresto's sales are estimated at $2.3 billion, benefiting from increased demand in China and Japan [5] - Kisqali's sales are projected at $1 billion, driven by its recognition in breast cancer treatment [6][7] - Kesimpta's sales are also expected to reach $1 billion, reflecting increased demand [7] - Cosentyx is anticipated to generate sales of $1.73 billion, supported by recent launches and volume growth [9] - Leqvio's sales estimates are $284 million, indicating strong growth in cholesterol management [10] - Pluvicto's sales are projected at $410 million, bolstered by FDA approval for expanded use [11] - Scemblix continues to see growth in chronic myeloid leukemia treatment, with strong demand expected [12] Recent Developments - Novartis acquired Regulus Therapeutics for $0.8 billion, adding farabursen to its pipeline, which targets autosomal dominant polycystic kidney disease [14] - Year-to-date, Novartis shares have increased by 27.3%, significantly outperforming the industry average of 1.8% [15]

Core Viewpoint - U.S. Bancorp (USB) is expected to report year-over-year increases in revenues and earnings for Q2 2025, benefiting from lower expenses and higher non-interest income [1] Group 1: Financial Performance Expectations - The company anticipates net interest income (NII) for Q2 2025 to be between $4.1 billion and $4.2 billion, with a consensus estimate of $4.01 billion, reflecting a marginal increase from the previous quarter [2][8] - The consensus estimate for total revenues in Q2 2025 is $7.06 billion, indicating a rise of 3.3% from the year-ago figure [13] - The Zacks Consensus Estimate for average earning assets is $611.2 million, suggesting a slight sequential increase [4] Group 2: Non-Interest Income and Trading Activity - Non-interest income is projected to rise by 3.3% due to gains in trading, mortgage, and card revenues, with total non-interest income estimated at $2.93 billion [9][8] - Trading volumes in equity derivatives and corporate bonds have increased, with the consensus estimate for commercial product revenues at $391 million, reflecting a 2.4% increase from the prior quarter [5] Group 3: Loan Activity and Market Conditions - Lending activity remained strong in Q2 2025, supported by a resilient labor market and easing inflation, with notable demand for commercial and industrial loans [3] - Mortgage banking revenues are expected to reach $179.6 million, indicating a 3.8% increase from the previous quarter, despite mortgage rates fluctuating in the mid-to-upper 6% range [6] Group 4: Expense Management and Asset Quality - The company aims to keep non-interest expenses at or below $4.2 billion in Q2 2025, despite higher costs related to compensation and employee benefits [10][9] - The Zacks Consensus Estimate for non-performing loans is $1.72 billion, indicating a rise of 1.8% from the prior quarter [10] Group 5: Earnings Expectations - U.S. Bancorp has a positive Earnings ESP of +0.21%, indicating a high likelihood of beating earnings estimates [11] - The consensus estimate for Q2 earnings is $1.07, reflecting a 9.2% increase from the year-ago reported number [12]

Core Viewpoint - Associated Banc-Corp (ASB) is positioned well to continue its trend of beating earnings estimates, with a solid history of performance in recent quarters [1][5]. Earnings Performance - For the last reported quarter, Associated Banc-Corp achieved earnings of $0.59 per share, surpassing the Zacks Consensus Estimate of $0.57 per share, resulting in a surprise of 3.51% [2]. - In the previous quarter, the company was expected to post earnings of $0.55 per share but delivered $0.57 per share, yielding a surprise of 3.64% [2]. Earnings Estimates and Predictions - Estimates for Associated Banc-Corp have been trending higher, supported by its history of earnings surprises [5]. - The company currently has an Earnings ESP (Expected Surprise Prediction) of +0.81%, indicating a bullish outlook from analysts regarding its earnings prospects [8]. - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) suggests a strong possibility of another earnings beat in the upcoming report [8]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6]. - The Earnings ESP metric compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7].